Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group

Martha Q. Lacy, Susanna Jacobus, Emily A. Blood, Neil E. Kay, S. Vincent Rajkumar, Philip R. Greipp

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.

Original languageEnglish (US)
Pages (from-to)1485-1489
Number of pages5
JournalLeukemia Research
Volume33
Issue number11
DOIs
StatePublished - Nov 2009

Keywords

  • Immunomodulatory therapy
  • Interleukin-12
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group'. Together they form a unique fingerprint.

  • Cite this